MAFDulaglutide Injection, Prefilled Pen 0.75 mg, 1.5 mg
For the treatment of type 2 diabetes mellitus:
1) As a triple therapy in combination with two oral anti-diabetic drug (OAD) therapies for patients with inadequate glycaemic control despite treatment with optimal doses of dual OAD therapy, or as a dual therapy in combination with one OAD therapy if a dual OAD therapy is contraindicated or not tolerated; and
2) in combination with insulin and metformin, unless metformin is contraindicated or not tolerated.